Using quantitative MRI to track cerebral

damage in multiple sclerosis: a

longitudinal study

1

2

3

4 5

6 7 8

11 12

13

14

15

16

17

18

19 20

21

2223

24

25

26

27

28

29

3031

32

33

34

35

36

Nora Vandeleene^a, Camille Guillemin^{a,b}, Solène Dauby^{a,c}, Florence Requier^{a,b}, Maëlle Charonitis^{a,b}, Daphne Chylinski^{a,b}, Evelyne Balteau^a, Pierre Maquet^{a,c}, Emilie Lommers^{a,c*}, Christophe Phillips^{a,d*}

- ^a GIGA CRC in vivo Imaging, University of Liège, Liège, Belgium
- b Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège,
 Belgium
 - ^c Clinical Neuroimmunology Unit, Neurology Department, CHU Liège, Belgium
 - ^d GIGA in silico Medicine, University of Liège, Liège, Belgium
 - * These authors equally contributed to the work.

Corresponding author: Christophe PHILLIPS

GIGA – CRC in vivo imaging B30

Allée du 6 août 4000 Liège Belgium

Word count:

Main text: 2685; Methods: 2367 (Total: 5052); Abstract: 320

Abbreviations:

ARoC: Annual Rate of Change, BPF: Brain Parenchymal Fraction, CDP: Confirmed Disability Progression, cMRI: Conventional Magnetic Resonance Imaging, CNS: Central Nervous System, GMF: Grey Matter Fraction, GLMM: General Linear Mixed Model, LF: Lesion Fraction, MPM: Multiparameter mapping, MRI: Magnetic Resonance Imaging, MS: Multiple Sclerosis, MT: Magnetization Transfer, MTR: Magnetization Transfer Ratio, MTsat: Saturated Magnetization Transfer, NABT: Normal Appearing Brain Tissue, NACGM: Normal Appearing Cortical Grey Matter, NADGM: Normal Appearing Deep Grey matter, NAWM: Normal Appearing White Matter, NEDA-3: No Evidence of Disease Activity, RRMS: Relapsing-Remitting Multiple Sclerosis, PD: Proton Density, PMS: Progressive Multiple Sclerosis, qMRI: Quantitative Magnetic Resonance Imaging, R1: Longitudinal Relaxation Rate (1/T1), R2*: Transverse Relaxation Rate (1/T2*), TIV: Total Intracranial Volume, TPM: Tissue Probability Map, US: Unified Segmentation,

NOTE: The swaring the description that he should not be used to guide clinical practice.

Abstract

Objectives:

Contrary to conventional MRI (cMRI), quantitative MRI (qMRI) quantifies tissue physical microstructural properties and improves the characterization of cerebral damages in relation with various neurological diseases. With a multi-parameter mapping (MPM) protocol, 4 parameter maps are constructed: saturated magnetization transfer (MTsat), proton density (PD), longitudinal relaxation (R1) and effective transverse relaxation (R2*) rates, reflecting tissue physical properties associated with iron and myelin contents. Here, we used qMRI to investigate the microstructural changes happening over time in multiple sclerosis (MS).

Methods:

Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, with at least one year separation between two acquisition sessions, and the evolution of their parameters was evaluated within several tissue classes: normal appearing white matter (NAWM), normal appearing cortical and deep gray matter (NACGM and NADGM) as well as focal white matter (WM) lesions. Brain tissue segmentation was performed using US-with-Lesion, an adapted version of the Unified Segmentation (US) algorithm accounting for the lesion tissue class, based on qMRI and FLAIR images. An individual annual rate of change for each qMRI parameter was computed, and its correlation to clinical status was evaluated. As for WM plaques, three areas were defined within them. A Generalized Linear Mixed Model (GLMM) tested the effect of area and time points, as well as their interaction on each median qMRI parameter value.

61 Results: 62 63 Patients with a better clinical evolution showed positive annual rate of change in MT and R2* within NAWM and NACGM, suggesting repair mechanisms in terms of 64 increased myelin content and/or axonal density. When examining focal WM lesions, 65 qMRI parameters within surrounding NAWM showed modification in terms of 66 reduction in MT, R1 and R2* combined with increased of PD even before any focal 67 68 lesion is visible on conventional FLAIR MRI. 69 70 Conclusion: 71 The results illustrate the benefit of multiple qMRI data in monitoring subtle changes 72 within normal appearing brain tissues and plaque dynamics in relation with tissue 73 repair or disease progression. 74 75 Keywords: 76 Quantitative MRI, relaxometry, longitudinal analysis, multiple sclerosis. 77 78

1. Introduction

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). The course of the disease may reflect the expression of two clinical phenomena, relapses of acute neurological symptoms followed by partial or complete recovery (remission), and progression, which refers to the steady and irreversible worsening of the clinical status. Relapses are mainly the expression of acute, focal, disseminated and recurrent inflammation occurring within the CNS (i.e., plaques). Plaques are the pathological hallmark of MS and harbor variable degrees of inflammation, demyelination, gliosis and axonal injury [1, 2]. Plaques are not restricted to the white matter (WM), but are also present in the cortex and deep grey matter (GM) [3-5]. The progressive accumulation of disability principally correlates with the early, diffuse and chronic inflammation within the normal appearing white matter (NAWM) and grey matter (NAGM) that is ultimately responsible for diffuse neuro-axonal loss and neurodegeneration [3, 4, 6]. By contrast, effective repair mechanisms can occur within focal lesions but probably also in normal appearing brain tissue (NABT) [7]. However, our understanding of these complex processes is still fragmentary. The difficulty of acquiring histopathological data on MS patients at various stages of the disease makes it challenging to describe the time course of injury and potential repair mechanisms in MS. Consequently, there is an important need for new imaging techniques to improve in-vivo monitoring of lesion formation, progression and repair in MS [8]. Conventional MRI (cMRI) readily depicts focal WM lesions on T2/FLAIR sequences and is able to distinguish between acute and allegedly chronic lesions, primarily on the evidence of bloodbrain barrier breakdown, as indicated by contrast enhancement. T2-hyperintensities in cMRI constitute the keystone of McDonald diagnostic criteria [9] and also make an important contribution to the monitoring of WM lesion burden. Unfortunately, cMRI sequences are not

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

able to efficiently assess cortical lesions or detect diffuse changes in NABT. This shortcoming is particularly apparent in the poor correlation of imaging results with short and long-term clinical outcomes [10]. Quantitative MRI (qMRI) potentially overcomes these limitations by quantifying physical microstructural properties of cerebral tissue in standardized units. Nevertheless, there exist challenging issues in performing longitudinal qMRI protocols. While qMRI in theoretically independent of the scanner used for acquisition as the parametric images rely on physical measurements of brain tissues, in reality the reproducibility is lower than expected, especially for semi-quantitative MT maps [11, 12]. Despite that, longitudinal analysis can still be accurate when identical sequences are used across scanning time points. In addition, qMRI is more sensitive but also more specific to microstructural properties of CNS tissues. Magnetization transfer ratio (MTR) was regularly linked to cerebral macromolecular content detected by a greater percentage loss of magnetization in voxels with a higher myelin content and axons density [13-15]. Post-mortem studies comparing the relative contribution of these two factors indicate that myelin has a stronger and more direct influence on MTR than the axonal density, which is considered as a T1-dependent effect. Tissue water content (inflammation, edema...), another T1-dependent effect, also accounts for MTR variability [14, 16, 17]. However, the MT saturation (MTsat) map offers a measure which, unlike MTR, is minimally affected by longitudinal relaxation and B1 mapping inhomogeneities [18], increasing its sensitivity to myelin content. Moreover, the brain contrast to noise ratio is larger for the MTsat map than for MTR, thus improving brain tissue segmentation in healthy subjects [14, 19]. Regarding the transverse relaxation time T2*, this measure reflects the effective decay of transverse magnetization T2, when considering intra-voxel magnetic field inhomogeneities. In the CNS, paramagnetic iron and diamagnetic myelin generate microscopic field gradients, thus shortening T2* and increasing the R2* (1/T2*) relaxation rate. Orientation

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

and density of myelin fibers are also a determining factor of R2* values [20-22]. Concerning the longitudinal relaxation rate R1 (1/T1) in the CNS, its three major determinants are tissue myelination and associated axons, iron and extracellular water contents [22-24]. Finally, proton density (PD) mostly reflects the free water content of the brain [25]. We have previously shown that a multivariate qMRI approach is useful to assess NABT microstructural alteration in a cross-sectional study comparing MS patients to healthy controls [26, 27]. Because each qMRI parameter is differently sensitive to histologically measured iron and myelin contents, this approach constitutes a fundamental tool for longitudinal in-vivo monitoring of MS lesions and NABT evolution at the tissue microstructural level. In this longitudinal study, we investigate the evolution of four simultaneously acquired qMRI parameters (MTsat, PD, R1, R2*) within NABT and WM lesions of 17 MS patients (relapsing remitting (RRMS) and progressive MS (PMS)) who were scanned two or three times with at least a one-year interval, following the same multi-parameter mapping (MPM) protocol at 3 Tesla [13, 28]. Segmentation of different cerebral tissue classes was computed using an advanced segmentation technique called Unified Segmentation with Lesion (USwL), an updated version of the traditional Unified Segmentation (US) algorithm from SPM. This pipeline accounts for lesions and relies on quantitative parameter maps rather than the standard weighted images. Here, we assessed the time course of parameter values in several tissue classes: NAWM, normal appearing cortical and deep GM (NACGM and NADGM) as well as focal WM lesions. In addition, we related the changes in NABT to clinical course.

2. Materials and methods

2.1 Population

Seventeen patients, recruited at the specialized MS outpatient clinic of the CHU Liège, Belgium, with a diagnosis of MS according to the McDonald criteria 2010 [29], were gathered from two studies: ten of them were part of the work reported by Lommers et al. 2019 [26], the other seven were recruited from another MS study taking place at the GIGA Cyclotron Research Centre – In Vivo Imaging (Liège, Belgium). Both were approved by the local ethics committee (approval numbers B707201213806 and B707201835630, respectively). All patients were followed up and scanned twice on the same 3T MRI scanner, every 1 to 3 years. For each of the 17 MS patients, data from two MRI sessions were available, at T0 and T1. This cohort included 11 RRMS patients and 6 (primary and secondary) PMS. Thirteen were receiving disease-modifying treatments (DMTs). The patients' median age was 36 years (range: 25-65) and the median time interval between two scans was 30 months (range: 14-61). Demographic data appears in Table 1. Extended individual information appears in Supplementary data.

	All Patients (n = 17)	
Age, y, median (range)	36 (25-65)	
Sex, F/M	7/10	
MS phenotype (RRMS/MS)	11/6	
Baseline disease duration, y, median (range)	3.4 (0.3-28)	
Baseline EDSS, median (range)	2.5 (1-6.5)	
Baseline number of relapses, median (range)	RRMS: 2 (1-5)	PMS: N/A
	RRMS:	PMS:
Disease-modifying treatment	First line, n: 5	Ocrelizumab, n: 2
	Second line, n: 6	None, n: 4

Table 1: Demographic data of the study sample

2.2 MR image acquisition

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

MRI data were acquired on a 3T whole-body MRI-scanner (Magnetom Prisma, Siemens Medical Solutions, Erlangen, Germany). The whole-brain MRI acquisitions included a multiparameter mapping protocol (MPM), from which one can simultaneously estimate (semi)quantitative maps of magnetization transfer saturation (MTsat), proton density (PD), transverse relaxation (R1) and effective longitudinal relaxation (R2*). This protocol arising from an international collaborative effort [13, 28], has already been used to study brain microstructure in various conditions including normal aging [28, 30, 31], brain tumor [32], Parkinson's disease [33-35] as well as MS. It consists of three co-localized 3D multi-echo fast low angle shot (FLASH) acquisitions at 1mm3 resolution and two additional calibration sequences to correct for inhomogeneities in the RF transmit field [36, 37]. The FLASH datasets were acquired with predominantly PD, T1 and MT weighting, referred to in the following as PDw, T1w and MTw echoes. All three had high bandwidth to minimize off-resonance and chemical shift artifacts. Volumes were acquired in 176 sagittal slices using a 256x224 voxel matrix. GRAPPA parallel imaging was combined with partial Fourier acquisition to speed up acquisition time to approximately 20 min. An additional FLAIR sequence was recorded with spatial resolution 1mm³ and TR/TE/TI=5000ms/516ms/1800ms. Extra B1 field mapping images (transmit B+ and receive B- fields) were also acquired to reduce spatial heterogeneities related to B1 effect. This was essential for proper quantification of T1 (or R1=1/T1) in particular. Finally, B0 field mapping images, corresponding to both magnitude images and pre-subtracted phase image, were acquired for image distortions corrections. A summary of the acquisition parameters appears in Supplementary data.

2.3 MR image processing

All data processing was performed in Matlab (The MathWorks Inc., Natick, MA, USA) using SPM12 (www.fil.ion.ucl.ac.uk/spm) and three additional dedicated SPM extensions: the Lesion Segmentation Tool (LST) version 1.2.3 (www.statisticalmodelling.de/lst.html) [38], the "quantitative MRI and in vivo histology using MRI" toolbox (hMRI, http://hmri.info) [13], and "US-with-Lesion" tool (USwL, https://github.com/CyclotronResearchCentre/USwLesion).

Quantitative maps - MTsat, PD, R1 and R2*- were estimated using the hMRI toolbox. T1w, PDw and MTw images acquired at multiple echo times (TE) were extrapolated to TE=0 to increase signal-to-noise ratio and remove the otherwise remaining R2* bias [13, 26, 39]. The TE=0 extrapolated MTw, PDw and T1w images were used to calculate MT saturation, R1 and apparent signal amplitude A* maps. PD maps were derived from A* maps, which are proportional to proton density. All quantitative maps were corrected for inhomogeneities

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

from local RF transmit field (B1+), and R1 quantitative maps were further corrected for imperfect RF spoiling using the strategy of Preibisch and Deichmann [40]. The receive bias field map (B1-) was used to correct PD maps for instrumental biases. The R2* map was estimated from all three multi-echo series (MTw, PDw and R1w) using the ESTATICS model [39]. For all sessions, spatial preprocessing involved different steps (Figure 1) after generating quantitative maps using the hMRI toolbox: within-patient registration brought the two serial MR data sets into the individual TO space, using the longitudinal registration tool from SPM [41]. For each individual patient, a preliminary WM lesion mask was generated based on FLAIR and T1w images by the lesion growth algorithm implemented in the LST toolbox [38], followed by manual corrections by an MS expert (EL) to remove aberrant/artefactual lesion detections [26]. The images were then segmented using the USwL toolbox, which consists of an extended version of the traditional Unified Segmentation (US) algorithm [42] and includes an additional tissue class representing the WM lesion(s). The USwL method internally generates a subjectspecific extended set of tissue probability maps (TPM) [43]: an extra tissue class, based on the smoothed preliminary lesion mask warped into template space (using cost function masking during normalization [44]), is added to account for the lesion, and the original white matter prior map is updated accordingly [45]. The grey matter TPM was not updated due to a very low number of lesions present in the cortical ribbon. Multi-channel segmentation was conducted, using MTsat, PD, R1 and FLAIR images. This pipeline did not use the PD-, T1- and MT-weighted images acquired for the MPM maps construction, but the parametric maps themselves instead. In this way, voxels do not depict MR intensities but rather physical quantitative parameters. The method generated the segmented tissue classes (a posteriori tissue, including lesion, probability maps), as well as spatial warping into standard template space. The preliminary lesion mask was used as input for the first session data (at T0) then the

229

230

231

232

233

234

235

236

237

a posteriori lesion map generated at this initial step served as prior to the subsequent session (at T1). Segmentation teased out the different tissue classes of interest: NAWM, NACGM and NADGM, as well as WM lesions. To analyze the microstructure within those tissue classes, a posteriori tissue maps were binarized and tissue-specific independent masks were constructed: each voxel is assigned to one single tissue class with the highest probability for that voxel (provided that this probability was above 0.2). The lesion binary mask was further cleaned for lesions <10mm³ which likely resulted from segmentation errors. Finally, binarized tissue class masks were in turn applied on the MPM maps to extract voxel values inside them.

239

240

241

242

243

244

245

Figure 1: Chartflow of data creation and processing (see text). MPM maps were created with the hMRI-toolbox, FLAIR images were directly acquired for both sessions (TO and T1). A preliminary mask was constructed based on TO FLAIR. All images (MPM and FLAIR, TO and T1) were co-registered to the MPM TO space. Segmentation using USwL allowed to isolate the different tissue classes.

2.4 Brain volume change

Volumetric changes were investigated using the USwL *a posteriori* tissue probability maps. The following measures of brain volume were computed for each session of each participant: (1) Total intra-cranial volume (TIV)=volume (NAWM + GM + CSF + lesions), (2) brain parenchymal fraction (BPF)=volume (NAWM + GM + lesions)/TIV, (3) GM fraction (GMF)=volume (GM)/TIV, and (4) lesion fraction (LF)=volume (lesion)/TIV. The percentage of change between both scanning sessions was evaluated for each volumetric measurement, then annualized changes were computed by dividing these measures by scan intervals (in years). Results were directly analysed with a t-test (testing if significantly different from 0 at p < .05), but also in the same way as the normal-appearing tissues MR parameters in relation to the patients' clinical status (see next section).

2.5 Analysis of normal-appearing tissues

The median value of quantitative MRI parameters was extracted from the three normal-appearing tissues (NAWM, NACGM and NADGM), and an individual annual rate of change (ARoC) was computed for each parameter in each tissue class, based on the initial and final values and accounting for the time interval (in years) between scans. This rate of change in qMRI parameters served as dependent variable in a general linear model testing the effect of clinical status:

$$Y = \beta_0 + \beta_1 X_{status} + \epsilon$$

Y is the ARoC for a qMRI parameter and tissue class, β 's are the regression parameters corresponding to the associated regressor (with β_0 the intercept), and ϵ the residuals. X_{status} is a binary categorical variable representing the patient's disease activity status: a status score of 1 was assigned to patients stable or improving from T0 to T1.

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

This patient status X_{status} was derived from one of two scores of disease activity. For evaluating RRMS patients, NEDA-3 (No Evidence of Disease Activity [46]), a composite of three related measures of disease activity, was used. A score of 0 was assigned in the presence of new clinical relapses and/or MRI activity (new or enlarged lesions visible on FLAIR T2 or Gadolinium-enhanced images) and/or disability progression based on Expanded Disability Status Scale (EDSS). For the PMS patients, disability progression captured by sustained EDSS changes over 6 months (Confirmed Disability Progression [47] at 6 months) indicated disability progression, resulting in a score of 0. For both RRMS and PMS patients, disability progression was defined as a 1.0 point increase if the EDSS score was ≤ 4.0 at baseline and as a 0.5 point increased if the baseline EDSS score was > 4.0. The threshold of 4.0 was proposed in this study because it is considered as a milestone regarding ambulatory performance. NEDA-3 and 6month CDP were evaluated at mid- and end-scanning interval, and a final status score of 0 was given only to patients for which disease activity or progression was noted in both cases, indicating a clear progression of the disease over the whole interscan interval. The influence of several clinical measurements such as 25 FWT, 9HPT and SDMT was also considered to refine the evaluation of disease activity. However complete data were lacking for several patients. Moreover, when available, these additional clinical parameters did not modify the final X_{status} . Permutation tests were employed for inferences [48]. R-squared value was tested against computed statistics after permutation of the data. For a number n of permutations, the X_{status} values were randomly shuffled (constructing a new regressor written X_{status}^{π}), tested against the unchanged response Y, and generating each time a permuted R-squared value (noted R_{π} , R_{obs} being the true R-squared value computed without permutation of the data).

The condition $X_{status} \neq X_{status}^{\pi}$ is verified at each permutation. After n permutations (with n

= 5000 in this study), a p-value was computed based on the following formula:

$$p = \frac{\#(R_{\pi} > R_{obs})}{n+1}$$

293

294

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

which estimates the probability of obtaining R_{obs} under the null hypothesis that $\it Y$ is not

correlated to X_{status} . The null hypothesis is rejected if p < .05 FDR-corrected for multiple

comparisons [49], for the 12 tests performed (3 tissue classes with 4 qMRI parameters).

Two-tailed t-tests were applied post-hoc on the significant results of permutation tests to

compare the ARoC distribution between disease status, i.e., $X_{status} = 0$ against $X_{status} = 1$.

Inferences were conducted at a significance level of .05.

The same pipeline was applied to the brain volumetric changes (BPF, GMF and LF) to test their

correlation to the disease activity status.

2.6 Analysis of lesions and peripheral tissues

For white matter lesions analysis, we did not use ARoC but exploited directly the qMRI parameters voxel values. Importantly, with USwL, the prior lesion mask is only used in a probabilistic way and the estimated posterior lesion map, obtained using MTsat, PD, R1 and FLAIR images, typically showed more extended lesion than clinically visible on the FLAIR image alone, as obtained with LST.

Therefore, we separated focal lesions clinically detected on FLAIR images from their peripheral regions detected on qMRI maps. Two different peripheral regions were considered: one for each time point (TO and T1). Therefore, at TO, three distinct lesion-related regions were isolated:

The lesions, as clinically defined, corresponding to hyperintensity on conventional FLAIR
 MR image acquired at TO (referred to as 'focal FLAIR lesion').

The peripheral region detected on gMRI maps at TO, not including the FLAIR lesion (referred to as 'initial peripheral lesion').

317

318

319

320

321

322

323

324

325

327

328

329

330

331

The peripheral region detected with the qMRI maps at T1, computed by masking out the T1 lesion mask with the T0 lesion mask (referred to as 'later peripheral lesion'). This region allows us to determine whether its microstructure at T0 forebodes a full-blown plaque, detectable during follow up.

The three areas were compared between each other and with NAWM, in order to characterize them on a microstructural basis (Figure 2). Only enlarging lesions were considered for these comparisons.




Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: Focal FLAIR lesion (dark gray area), Initial peripheral lesion detected at TO (medium gray area), Later peripheral lesion detected at T1 (dashed, left, and light gray, right, area)

NAWM region consisted of all white matter voxels which did not belong to any of the three lesion-related regions. The four areas were independent as no voxel could belong to more than one class at the same time. For all participants, MTsat, PD, R1 and R2* median values were extracted from each lesion area, considering lesions individually (between 2 and 66 measurements per subject). Similarly, the median qMRI values within NAWM were also extracted (one measurement per subject). These values were extracted from TO and T1 scans separately. Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary, NC). None of the qMRI parameter was normally distributed, therefore we applied a log transformation on each of them prior to statistical analysis. For each qMRI parameter, a separate Generalized Linear Mixed Model (GLMM) tested the effect of areas (NAWM and the three lesion-related areas), and time points (T0 and T1), as well as their interaction (i.e., area*time), on the median gMRI parameter value, with a first-order autoregressive variance/covariance model and participants as a random factor (intercept). The degrees of freedom were estimated using Kenward-Roger's method. Statistical significance was estimated at p < .05 after adjustment for multiple comparison using Tukey's procedure.

3. Results

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

3.1 Volume changes

BPF annually decreased between T0 and T1 by -0.67 ± 1.12% (significantly different from zero; paired-sample t-tests; t(16) = 2.57; p = .0204) whereas LF increased by 22.88 \pm 26.13% (t(16) = -3.70; p = .0019). GMF non-significantly decreased by -0.30 ± 1.44%.

3.2 Analysis of normal-appearing tissues

354

355

356

358

359

360

361

362

363

364

365

As expected, changes in MTsat and R2* within NABT between T0 and T1 varied across subjects (Figure 3). PD and R1 exhibited similar behaviors, see Supplementary data.




Figure 3: Line plots illustrating individual ARoC's for MTsat (left) and R2* (right) in NAWM. Each line corresponds to one subject. Dotted lines represent increasing rates.

At the group level, with the GLM analysis and permutation inference, we observed that the ARoC of MTsat and R2* positively regressed with disease status as follows (Table 2): MTsat in NAWM and NACGM and R2* in NAWM significantly increase in patients who fare well $(X_{status} = 1).$

perpetuity.

It is made available under a CC-BY 4.0 International license .

366

367368

369

370

371

372

373

374

375

377

378

379

	NAWM	NACGM	NADGM
MT	0.039 (.011)*	0.017 (.007)*	0.004 (.749)
PD	-0.018 (.670)	0.405 (.225)	0.250 (.552)
R1	0.009 (.139)	0.004 (.471)	0.010 (.111)
R2*	0.295 (.002)*	0.121 (.092)	0.066 (.770)
BPF	-0.884 (.1562)		
LF	21.23 (.1082)		

Table 2: Regression coefficients and their associated p-values (in parentheses) for the effects of X_{status} on the individual ARoC for each qMRI parameter (MTsat, PD, R1 and R2*) and for volumetric measurements (BPF and LF).

Post-hoc t-tests applied on these significant results for a clearer illustration of the difference in disease status (Figure 4) were all significant at a level of .05.




Figure 4: Violin plots of significant change rates in microstructure with respect to X_{status} .

From left to right: MT in NAWM, MT in NACGM, R2* in NAWM. * P < .05.

^{*} Results significant at p < .05, FDR corrected.

perpetuity.

It is made available under a CC-BY 4.0 International license.

Regarding BPF and LF, their correlation to the disease activity status was not significant (Table 2), suggesting that qMRI parameters are more sensitive to subtle microstructural changes in NABT over time than global morphological measurements

3.3 Analysis of lesion microstructure

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

The number of enlarging WM lesions between T0 and T1 varied from 2 to 66 across patients, corresponding on average to 63% (±31%) of the number of initial focal lesions. The number of enlarging lesions did not significantly differ between patients' disease status groups (t(15) = .244, p = .811). GLMMs found a significant effect of areas (3 lesion regions and NAWM) for MT, R1, R2* and PD median (MT: $F_3 = 35.34$, p < .0001, PD: $F_3 = 68.03$, p < .0001, R1: $F_3 = 40.26$, p < .0001, R2*: $F_3 = 40.26$ 32.32, p < .0001). By contrast, neither time effect (T0 vs T1; MT: $F_3 = 0.36$, p = .5481, PD: $F_3 = 0.36$ 1.20, p = .2735, R1: $F_3 = 2.05$, p = .1520, R2*: $F_3 = 2.86$, p = .0911), nor the area*time interaction (MT: $F_3 = 0.09$, p = .9671, PD: $F_3 = 0.14$, p = .9346, R1: $F_3 = 0.14$, p = .9331, R2*: $F_3 = 0.40$, p = .7565) were significant, suggesting the microstructural stability of the initial lesion core. Post-hoc tests confirmed significant differences between the four tissue areas. MTsat, R1 and R2* were significantly larger from FLAIR lesion to initial peripheral lesion, from initial to later peripheral lesion and from later peripheral lesion to NAWM. The reverse was observed for PD. The significant difference in parameters between initial and later peripheral lesion at TO suggests that subtle microstructural changes appear in the periphery of the initial lesion, months before their detection as focal FLAIR lesions at T1. Adjusted p-values appear in Figure 5. Detailed statistical results of the GLMM's appear in Supplementary data.




Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time

TO and T1. P-values were obtained with *post-hoc* tests on the tissue area effect. * P < .05.

4. Discussion

This longitudinal study followed up volumetric data and qMRI brain metrics (MTsat, PD, R1, R2*) in 17 MS patients for a median time interval of 30 months. The main results are threefold. First, the microstructure of normal appearing brain tissues changes over time and these modifications concur with, and potentially drive, clinical evolution. This critical finding suggests that repair mechanism and edema resorption can be monitored *in vivo*. Second, the microstructure within WM plaques is remarkably heterogeneous. Importantly, at their periphery, microstructural alterations foreshadow their expansion, as detected by conventional MRI. Third, as expected, we observed a small but significant brain atrophy and lesion load increase with time.

Quantitative MRI parameter time course within NABT

In this study, we used a multiparameter mapping protocol that was gradually optimized and validated for multi-centric studies [12]. It provides high-resolution maps of multiple qMRI parameters from data acquired during a single scanning session of acceptable duration. A number of cross-sectional studies using a combination of MT, R1, R2* or PD parameters reported significant changes in the microstructure of NABT in MS [26, 50-56]. By contrast, longitudinal analyses of multiparameter qMRI data are scarce. A progressive shortening of T2/T2* [57] or increase in R2* [58-60] was reported within the basal ganglia, suggesting increased of myelin and/or iron contents as well as edema resorption. Likewise, PD and T1 increased within a year, suggesting a demyelination and/or axonal loss [61]. MTR progressively

decreases in NAWM of MS patients over one [62] or two years [63]. These abnormalities tend to be more pronounced in progressive phenotypes [64] and were associated to a slow, diffuse and global myelin pathology.

Here, we showed that MTsat within NAWM and NACGM and R2* values within NAWM increase in clinically stable or improving patients. Because MTsat and R2* both correlate with myelin content [14, 30, 31, 65-67], our results suggest repair mechanisms within NABT of patients who are responding to disease modifying treatments, despite the initial myelin/axonal loss and independently from WM focal lesion evolution. These results echo cross-sectional analyses showing that healthy controls (HC) have higher MTsat and R2* values within the same tissue classes compared to MS patients [26]. Annual rates of change of R1 and PD within NABT were not significantly associated with the individual clinical status in this study, although R1 reduction within NABT has already been reported in cross sectional [26, 53, 54] and longitudinal [61] studies comparing MS subjects to HC.

Lesion microstructure

Focal inflammatory demyelinating lesions have been extensively characterized and are traditionally classified as active, chronic active (smoldering) or inactive plaques according to the presence and distribution of plaque-infiltrating macrophages/microglia [68-70]. Focal WM pathology is a constantly evolving process including episodes of demyelination and remyelination but also accumulation of irreversible axonal damage. Age, disease duration, clinical phenotype as well as disease modifying treatment all contribute to the dynamic nature of focal WM pathology [69, 71]. This accounts for the large inter- and intra-individual heterogeneity of MS, which conventional MRI is largely unable to capture. By contrast, quantitative MRI parameters are sensitive to myelin, axonal as well as iron contents and appear as promising markers of plaque dynamics. For instance, MTR was shown to sharply

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

decrease within gadolinium enhancing lesions before recovering during the subsequent months [72-74]. Likewise, reduction of MTR within NAWM, days to weeks before the formation of a new active lesion was also demonstrated [75, 76], and long-term MTR changes in WM plagues were observed in relation with disease progression [64, 77]. The present study broadens the quantitative characterization of plaque dynamics, in keeping with previous longitudinal studies [57, 78]. Two important findings emerge from the results. First, qMRI refines lesion segmentation, as compared to the processing based on the sole FLAIR image. In consequence, the initial lesion revealed by qMRI is typically wider that the plaque detected in FLAIR. Its periphery is characterized by a decrease in MTsat and R2* as compared to NAWM, suggesting an incipient demyelination, reminiscent of the so-called 'periplaques' [79]. Moreover, MTsat, R2* and R1 values progressively decrease from NAWM to plaque core, suggesting a centripetal loss of myelin content. Second, plaque microstructure is altered in plaque periphery before any observable change in conventional MRI signals. This finding suggests, in keeping with neuropathological observations [69, 71, 80, 81] that subclinical ongoing inflammation and/or demyelination takes place in the periphery of an active plaque, well before it is detectable on FLAIR or T1 post-gadolinium sequences. If confirmed on larger population samples, this finding might significantly modify treatment management in MS patients. Oddly enough, plaque qMRI parameters did not significantly change across time. Because iron concentration increases within chronic active or smoldering lesions [82, 83], we were expecting a progressive increase in R2* value. This negative result might be due to the small sample size, the short period of follow up or the limited sensitivity of R2* to local iron concentration as compared to the combined use of R2* and quantitative susceptibility mapping (QSM) [21].

Volumetric Data

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

CNS atrophy occurs in all stages of MS, since the preclinical phase of the disease and progresses throughout its course, at a much higher rate than one reported in normal aging [84-87]. In this study, the annual brain percentage volume loss at the group level was > 0.4%, which is in line with previous publications [88]. We also showed a significant increase in lesion fraction. Volumetric data (ARoC's) were highly variable across subjects: changes in BPF range from -2.52 to 1.17% and LF from -0.78 to 103.06%. This variability arises from a large number of factors which do or do not relate to MS: age, disease duration, disease phenotype, disease modifying treatment, circadian rhythm, hydration... [86, 87]. Moreover, annual changes in brain parenchymal fraction as well as lesion fraction only partially correlated to patients' disease status, in accordance with a large amount of publications [61, 89]. This highlights the lack of specificity and sensitivity of volumetric measurements, at least at the individual level.

Study limitation

As mentioned earlier, the main limitation of the study was the small size and heterogeneous aspect of the present dataset. Indeed, it is composed of only 17 patients, with a rather broad range of characteristics such as age, disease duration, disease phenotype, disease modifying treatment, etc., which are known to influence the disability state of the patient and thus their ability to put together repair mechanisms within cerebral tissues [1, 69-71, 90, 91]. In addition, the time interval between two scanning sessions varied quite a lot across patients (between 14 and 61 months), although it was brought back to an annual rate where possible. All of these features were imposed by standard clinical follow up. Therefore, these results should not be over-interpreted but are nevertheless promising and call for a replication with a larger and more homogeneous or controlled set of MS patients.

501

502

503

504

505

506

507

508

509

510 511 512

513

514

5. Conclusion These preliminary results highlight the relevance of multiple qMRI data in the monitoring of subtle changes within NABT and plaque dynamics in relation with repair or disease progression. Of course, large scale longitudinal study would be needed to reproduce these findings and better exploit the full potential of qMRI parameters. 6. Declarations of interest None. 7. Funding NV, EL and CP are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS Belgium)

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

8. References [1] Lassmann, Hans. "Pathology and Disease Mechanisms in Different Stages of Multiple Sclerosis." Journal of the Neurological Sciences 333, no. 1–2 (October 2013): 1-4. https://doi.org/10.1016/j.jns.2013.05.010. [2] Trapp, Bruce D., John Peterson, Richard M. Ransohoff, Richard Rudick, Sverre Mörk, and Lars Bö. "Axonal Transection in the Lesions of Multiple Sclerosis." New England Medicine Journal 338, no. (January 29, 1998): 278-85. https://doi.org/10.1056/NEJM199801293380502. [3] Haider, Lukas, Tobias Zrzavy, Simon Hametner, Romana Höftberger, Francesca Bagnato, Günther Grabner, Siegfried Trattnig, Sabine Pfeifenbring, Wolfgang Brück, and Hans Lassmann. "The Topograpy of Demyelination and Neurodegeneration in the Brain." Multiple Sclerosis Brain 139, no. 3 (March 2016): 807–15. https://doi.org/10.1093/brain/awv398. [4] Kutzelnigg, Alexandra, Claudia F. Lucchinetti, Christine Stadelmann, Wolfgang Brück, Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E. Parisi, and Hans Lassmann. "Cortical Demyelination and Diffuse White Matter Injury in Multiple Sclerosis." Brain 128, no. 11 (November 1, 2005): 2705–12. https://doi.org/10.1093/brain/awh641.

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

[5] Gh Popescu, Bogdan F, and Claudia F Lucchinetti. "Meningeal and Cortical Grey Matter Pathology in Multiple Sclerosis." BMC Neurology 12, no. 1 (December 2012): 11. https://doi.org/10.1186/1471-2377-12-11. [6] Frischer, Josa M., Stephan Bramow, Assunta Dal-Bianco, Claudia F. Lucchinetti, Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, and Hans Lassmann. "The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis Brains." Brain 132, no. 5 (May 2009): 1175-89. https://doi.org/10.1093/brain/awp070. [7] Brown, Robert A., Sridar Narayanan, and Douglas L. Arnold. "Imaging of Repeated Episodes of Demyelination and Remyelination in Multiple Sclerosis." NeuroImage: Clinical 6 (2014): 20–25. https://doi.org/10.1016/j.nicl.2014.06.009. [8] Wang, Chenyu Tim, Michael Barnett, and Yael Barnett. "Imaging the Multiple Sclerosis Lesion: Insights into Pathogenesis, Progression and Repair." Current Opinion in Neurology 32, 3 (June 2019): 338-45. no. https://doi.org/10.1097/WCO.0000000000000698. [9] Thompson, Alan J, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, et al. "Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria." The Lancet Neurology 17, no. 2 (February 2018): 162-73. https://doi.org/10.1016/S1474-4422(17)30470-2.

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

[10] Barkhof, Frederik. "The Clinico-Radiological Paradox in Multiple Sclerosis Revisited:" Current Opinion in Neurology 15, no. 3 (June 2002): 239-45. https://doi.org/10.1097/00019052-200206000-00003. [11] Gracien, René-Maxime, Michelle Maiworm, Nadine Brüche, Manoj Shrestha, Ulrike Nöth, Elke Hattingen, Marlies Wagner, and Ralf Deichmann. "How Stable Is Quantitative MRI? - Assessment of Intra- and Inter-Scanner-Model Reproducibility Using Identical Acquisition Sequences and Data Analysis Programs." NeuroImage 207 (February 2020): 116364. https://doi.org/10.1016/j.neuroimage.2019.116364. [12] Leutritz, Tobias, Maryam Seif, Gunther Helms, Rebecca S Samson, Armin Curt, Patrick Freund, and Nikolaus Weiskopf. "Multiparameter Mapping of Relaxation (R1, R2 *), Proton Density and Magnetization Transfer Saturation at 3 T: A Multicenter Dualvendor Reproducibility and Repeatability Study." Human Brain Mapping 41, no. 15 (October 15, 2020): 4232-47. https://doi.org/10.1002/hbm.25122. [13] Tabelow, Karsten, Evelyne Balteau, John Ashburner, Martina F. Callaghan, Bogdan Draganski, Gunther Helms, Ferath Kherif, et al. "HMRI – A Toolbox for Quantitative MRI in Neuroscience and Clinical Research." NeuroImage 194 (July 2019): 191-210. https://doi.org/10.1016/j.neuroimage.2019.01.029. [14] Schmierer, Klaus, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, and David H. Miller. "Magnetization Transfer Ratio and Myelin in Postmortem Multiple

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

Sclerosis Brain." Annals of Neurology 56, no. 3 (September 2004): 407-15. https://doi.org/10.1002/ana.20202. [15] Callaghan, Martina F., Gunther Helms, Antoine Lutti, Siawoosh Mohammadi, and Nikolaus Weiskopf. "A General Linear Relaxometry Model of R 1 Using Imaging Data: General Linear Relaxometry Model of R1." Magnetic Resonance in Medicine 73, no. 3 (March 2015): 1309-14. https://doi.org/10.1002/mrm.25210. [16] Van Waesberghe, J. H. T. M., W. Kamphorst, C. J. A. De Groot, M. A. A. Van Walderveen, J. A. Castelijns, R. Ravid, G. J. Lycklama a Nijeholt, et al. "Axonal Loss in Multiple Sclerosis Lesions: Magnetic Resonance Imaging Insights into Substrates of Disability." Annals of Neurology 46, no. 5 (November 1999): 747–54. https://doi.org/10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4. [17] Mottershead, J. P., K. Schmierer, M. Clemence, J. S. Thornton, F. Scaravilli, G. J. Barker, P. S. Tofts, et al. "High Field MRI Correlates of Myelin Content and Axonal Density in Multiple Sclerosis." Journal of Neurology 250, no. 11 (November 1, 2003): 1293-1301. https://doi.org/10.1007/s00415-003-0192-3. [18] Lema, Alfonso, Courtney Bishop, Omar Malik, Miriam Mattoscio, Rehiana Ali, Richard Nicholas, Paolo A. Muraro, Paul M. Matthews, Adam D. Waldman, and Rexford D. Newbould. "A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis: MT of Brain and c-Spine in MS."

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

Journal of Neuroimaging 27, 2 (March 2017): 221-26. no. https://doi.org/10.1111/jon.12377. [19] Helms, Gunther, Henning Dathe, and Peter Dechent. "Modeling the Influence of TR and Excitation Flip Angle on the Magnetization Transfer Ratio (MTR) in Human Brain Obtained from 3D Spoiled Gradient Echo MRI." Magnetic Resonance in Medicine 64, no. 1 (July 2010): 177-85. https://doi.org/10.1002/mrm.22379. [20] Bagnato, Francesca, Simon Hametner, Emma Boyd, Verena Endmayr, Yaping Shi, Vasiliki Ikonomidou, Guanhua Chen, et al. "Untangling the R2* Contrast in Multiple Sclerosis: A Combined MRI-Histology Study at 7.0 Tesla." Edited by Quan Jiang. PLOS ONE 13, no. 3 (March 21, 2018): e0193839. https://doi.org/10.1371/journal.pone.0193839. [21] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation Study." NeuroImage 179 (October 2018): 117-33. https://doi.org/10.1016/j.neuroimage.2018.06.007. [22] Stüber, Carsten, Markus Morawski, Andreas Schäfer, Christian Labadie, Miriam Wähnert, Christoph Leuze, Markus Streicher, et al. "Myelin and Iron Concentration in the Human Brain: A Quantitative Study of MRI Contrast." NeuroImage 93 (June 2014): 95-106. https://doi.org/10.1016/j.neuroimage.2014.02.026.

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

[23] Granziera, Cristina, Jens Wuerfel, Frederik Barkhof, Massimiliano Calabrese, Nicola De Stefano, Christian Enzinger, Nikos Evangelou, et al. "Quantitative Magnetic Resonance Imaging towards Clinical Application in Multiple Sclerosis." Brain 144, no. 5 (June 22, 2021): 1296–1311. https://doi.org/10.1093/brain/awab029. [24] Kolb, Hadar, Martina Absinta, Erin S. Beck, Seung-Kwon Ha, Yeajin Song, Gina Norato, Irene Cortese, Pascal Sati, Govind Nair, and Daniel S. Reich. "7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions." Annals of Neurology 90, no. 4 (October 2021): 612-26. https://doi.org/10.1002/ana.26194. [25] Edwards, Luke J., Evgeniya Kirilina, Siawoosh Mohammadi, and Nikolaus Weiskopf. "Microstructural Imaging of Human Neocortex in Vivo." NeuroImage 182 (November 2018): 184–206. https://doi.org/10.1016/j.neuroimage.2018.02.055. [26] Lommers, Emilie, Jessica Simon, Gilles Reuter, Gaël Delrue, Dominique Dive, Christian Degueldre, Evelyne Balteau, Christophe Phillips, and Pierre Maquet. "Multiparameter MRI Quantification of Microstructural Tissue Alterations in Multiple Sclerosis." NeuroImage: Clinical 23 (2019):101879. https://doi.org/10.1016/j.nicl.2019.101879. [27] Lommers, Emilie, Camille Guillemin, Gilles Reuter, Eve Fouarge, Gaël Delrue, Fabienne Collette, Christian Degueldre, Evelyne Balteau, Pierre Maquet, and Christophe Phillips. "VOXEL-BASED Quantitative MRI Reveals Spatial Patterns of Grey

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

Matter Alteration in Multiple Sclerosis." Human Brain Mapping 42, no. 4 (March 2021): 1003-12. https://doi.org/10.1002/hbm.25274. [28] Draganski, B., J. Ashburner, C. Hutton, F. Kherif, R.S.J. Frackowiak, G. Helms, and N. Weiskopf. "Regional Specificity of MRI Contrast Parameter Changes in Normal Ageing Revealed by Voxel-Based Quantification (VBQ)." NeuroImage 55, no. 4 (April 2011): 1423-34. https://doi.org/10.1016/j.neuroimage.2011.01.052. [29] Polman, Chris H., Stephen C. Reingold, Brenda Banwell, Michel Clanet, Jeffrey A. Cohen, Massimo Filippi, Kazuo Fujihara, et al. "Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria." Annals of Neurology 69, no. 2 (February 2011): 292-302. https://doi.org/10.1002/ana.22366. [30] Callaghan, Martina F., Patrick Freund, Bogdan Draganski, Elaine Anderson, Marinella Cappelletti, Rumana Chowdhury, Joern Diedrichsen, et al. "Widespread Age-Related Differences in the Human Brain Microstructure Revealed by Quantitative Magnetic Resonance Imaging." Neurobiology of Aging 35, no. 8 (August 2014): 1862-72. https://doi.org/10.1016/j.neurobiolaging.2014.02.008. [31] Carey, Daniel, Francesco Caprini, Micah Allen, Antoine Lutti, Nikolaus Weiskopf, Geraint Rees, Martina F. Callaghan, and Frederic Dick. "Quantitative MRI Provides Markers of Intra-, Inter-Regional, and Age-Related Differences in Young Adult Cortical Microstructure." Neurolmage 182 (November 2018): 429-40.

https://doi.org/10.1016/j.neuroimage.2017.11.066.

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

[32] Reuter, Gilles, Emilie Lommers, Evelyne Balteau, Jessica Simon, Christophe Phillips, Felix Scholtes, Didier Martin, Arnaud Lombard, and Pierre Maguet. "Multiparameter Quantitative Histological MRI Values in High-Grade Gliomas: A Potential Biomarker of Tumor Progression." Neuro-Oncology Practice 7, no. 6 (December 4, 2020): 646-55. https://doi.org/10.1093/nop/npaa047. [33] Depierreux, Frédérique, Eric Parmentier, Laurane Mackels, Katherine Baquero, Christian Degueldre, Evelyne Balteau, Eric Salmon, et al. "Parkinson's Disease Multimodal Imaging: F-DOPA PET, Neuromelanin-Sensitive and Quantitative Iron-Sensitive MRI." Npj Parkinson's Disease 7, no. 1 (December 2021): 57. https://doi.org/10.1038/s41531-021-00199-2. [34] Nürnberger, Lucas, René-Maxime Gracien, Pavel Hok, Stephanie-Michelle Hof, Udo Rüb, Helmuth Steinmetz, Rüdiger Hilker, Johannes C. Klein, Ralf Deichmann, and Simon Baudrexel. "Longitudinal Changes of Cortical Microstructure in Parkinson's Disease Assessed with T1 Relaxometry." NeuroImage: Clinical 13 (2017): 405–14. https://doi.org/10.1016/j.nicl.2016.12.025. [35] Klein, J.C., M. Rolinski, L. Griffanti, K. Szewczyk-Krolikowski, F. Baig, C. Ruffmann, A.R. Groves, R.A.L. Menke, M.T. Hu, and C. Mackay. "Cortical Structural Involvement and Cognitive Dysfunction in Early Parkinson's Disease." NMR in Biomedicine 31, no. 4 (April 2018): e3900. https://doi.org/10.1002/nbm.3900.

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

[36] Lutti, Antoine, Chloe Hutton, Jürgen Finsterbusch, Gunther Helms, and Nikolaus Weiskopf. "Optimization and Validation of Methods for Mapping of the Radiofrequency Transmit Field at 3T: Optimized RF Transmit Field Mapping at 3T." Magnetic Resonance in Medicine 64, no. 1 (July 2010): 229-38. https://doi.org/10.1002/mrm.22421. [37] Lutti, Antoine, Joerg Stadler, Oliver Josephs, Christian Windischberger, Oliver Speck, Johannes Bernarding, Chloe Hutton, and Nikolaus Weiskopf. "Robust and Fast Whole Brain Mapping of the RF Transmit Field B1 at 7T." Edited by Wang Zhan. PLoS ONE 7, no. 3 (March 12, 2012): e32379. https://doi.org/10.1371/journal.pone.0032379. [38] Schmidt, Paul, Christian Gaser, Milan Arsic, Dorothea Buck, Annette Förschler, Achim Berthele, Muna Hoshi, et al. "An Automated Tool for Detection of FLAIR-Hyperintense White-Matter Lesions in Multiple Sclerosis." NeuroImage 59, no. 4 (February 2012): 3774–83. https://doi.org/10.1016/j.neuroimage.2011.11.032. [39] Weiskopf, Nikolaus, Martina F. Callaghan, Oliver Josephs, Antoine Lutti, and Siawoosh Mohammadi. "Estimating the Apparent Transverse Relaxation Time (R2*) from Images with Different Contrasts (ESTATICS) Reduces Motion Artifacts." Frontiers in Neuroscience 8 (September 10, 2014). https://doi.org/10.3389/fnins.2014.00278. [40] Preibisch, C., and R. Deichmann. "Influence of RF Spoiling on the Stability and Accuracy of T₁ Mapping Based on Spoiled FLASH with Varying Flip Angles: Influence of 726 RF Spoiling on T₁ Mapping." Magnetic Resonance in Medicine 61, no. 1 (January 2009): 727 125-35. https://doi.org/10.1002/mrm.21776. 728 729 [41] Ashburner, John. "Symmetric Diffeomorphic Modeling of Longitudinal Structural 730 MRI." Frontiers in Neuroscience 6 (2013). https://doi.org/10.3389/fnins.2012.00197. 731 [42] Ashburner, John, and Karl J. Friston. "Unified Segmentation." NeuroImage 26, no. 732 3 (July 2005): 839-51. https://doi.org/10.1016/j.neuroimage.2005.02.018. 733 734 735 [43] Lorio, S., S. Fresard, S. Adaszewski, F. Kherif, R. Chowdhury, R.S. Frackowiak, J. 736 Ashburner, et al. "New Tissue Priors for Improved Automated Classification of 737 Subcortical Brain Structures on MRI." NeuroImage 130 (April 2016): 157-66. 738 https://doi.org/10.1016/j.neuroimage.2016.01.062. 739 740 [44] Andersen, Sarah M., Steven Z. Rapcsak, and Pélagie M. Beeson. "Cost Function 741 Masking during Normalization of Brains with Focal Lesions: Still a Necessity?" 742 Neurolmage 53, 1 (October 2010): 78-84. no. 743 https://doi.org/10.1016/j.neuroimage.2010.06.003. 744 745 [45] Moon, Nathan, Elizabeth Bullitt, Koen van Leemput, and Guido Gerig. "Automatic 746 Brain and Tumor Segmentation." In Medical Image Computing and Computer-Assisted 747 Intervention — MICCAI 2002, edited by Takeyoshi Dohi and Ron Kikinis, 2488:372–79. 748 Lecture Notes in Computer Science. Berlin, Heidelberg: Springer Berlin Heidelberg,

2002. https://doi.org/10.1007/3-540-45786-0 46.

749

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

[46] Pandit, Lekha. "No Evidence of Disease Activity (NEDA) in Multiple Sclerosis -Shifting the Goal Posts." Annals of Indian Academy of Neurology 22, no. 3 (2019): 261. https://doi.org/10.4103/aian.AIAN 159 19. [47] Wiendl, Heinz, and Sven G. Meuth. "Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis." Drugs 75, no. 9 (June 2015): 947-77. https://doi.org/10.1007/s40265-015-0411-0. [48] Anderson, Marti J. "Permutation Tests for Univariate or Multivariate Analysis of Variance and Regression." Canadian Journal of Fisheries and Aquatic Sciences 58, no. 3 (March 1, 2001): 626-39. https://doi.org/10.1139/f01-004. [49] Yoav Benjamini and Yosef Hochberg. "Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing" Journal of the Royal Statistical Society. Series B (Methodological), Vol. 57, No.1 (1995), 289-300. [50] Andica, Christina, Akifumi Hagiwara, Koji Kamagata, Kazumasa Yokoyama, Keigo Shimoji, Asami Saito, Yuki Takenaka, et al. "Gray Matter Alterations in Early and Late Relapsing-Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance Imaging." Scientific Reports 9, no. 1 (December 2019): 8147. https://doi.org/10.1038/s41598-019-44615-3.

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

[51] Bonnier, Guillaume, Alexis Roche, David Romascano, Samanta Simioni, Djalel Meskaldji, David Rotzinger, Ying-Chia Lin, et al. "Advanced MRI Unravels the Nature of Tissue Alterations in Early Multiple Sclerosis." Annals of Clinical and Translational Neurology 1, no. 6 (June 2014): 423–32. https://doi.org/10.1002/acn3.68. [52] Engström, Maria, Jan B. M. Warntjes, Anders Tisell, Anne-Marie Landtblom, and Peter Lundberg. "Multi-Parametric Representation of Voxel-Based Quantitative Magnetic Resonance Imaging." Edited by Friedemann Paul. PLoS ONE 9, no. 11 (November 13, 2014): e111688. https://doi.org/10.1371/journal.pone.0111688. [53] Gracien, René-Maxime, Alina Jurcoane, Marlies Wagner, Sarah C. Reitz, Christoph Mayer, Steffen Volz, Stephanie-Michelle Hof, et al. "Multimodal Quantitative MRI Assessment of Cortical Damage in Relapsing-Remitting Multiple Sclerosis: Cortical Quantitative MRI in RRMS." Journal of Magnetic Resonance Imaging 44, no. 6 (December 2016): 1600-1607. https://doi.org/10.1002/jmri.25297. [54] Neema, Mohit, James Stankiewicz, Ashish Arora, Venkata S.R. Dandamudi, Courtney E. Batt, Zachary D. Guss, Ali Al-Sabbagh, and Rohit Bakshi. "T1- and T2-Based MRI Measures of Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis." Journal of Neuroimaging 17 (April 2007): 16S-21S. https://doi.org/10.1111/j.1552-6569.2007.00131.x.

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

[55] Reitz, Sarah C., Stephanie-Michelle Hof, Vinzenz Fleischer, Alla Brodski, Adriane Gröger, René-Maxime Gracien, Amgad Droby, et al. "Multi-Parametric Quantitative MRI of Normal Appearing White Matter in Multiple Sclerosis, and the Effect of Disease Activity on T2." Brain Imaging and Behavior 11, no. 3 (June 2017): 744-53. https://doi.org/10.1007/s11682-016-9550-5. [56] Stevenson, V.L, G.J.M Parker, G.J Barker, K Birnie, P.S Tofts, D.H Miller, and A.J Thompson. "Variations in T1 and T2 Relaxation Times of Normal Appearing White Matter and Lesions in Multiple Sclerosis." Journal of the Neurological Sciences 178, no. 2 (September 2000): 81-87. https://doi.org/10.1016/S0022-510X(00)00339-7. [57] Bonnier, Guillaume, Benedicte Maréchal, Mário João Fartaria, Pavel Falkowskiy, José P. Marques, Samanta Simioni, Myriam Schluep, et al. "The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients." Frontiers in Neurology 8 (September 27, 2017): 506. https://doi.org/10.3389/fneur.2017.00506. [58] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Gregg Blevins, and Alan H. Wilman. "Discriminative Analysis of Regional Evolution of Iron and Myelin/Calcium in Deep Gray Matter of Multiple Sclerosis and Healthy Subjects: Analysis of Iron and Myelin in MS." Journal of Magnetic Resonance Imaging 48, no. 3 (September 2018): 652-68. https://doi.org/10.1002/jmri.26004.

perpetuity.

It is made available under a CC-BY 4.0 International license.

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

[59] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Peter Seres, Gregg Blevins, and Alan H. Wilman. "Five Year Iron Changes in Relapsing-Remitting Multiple Sclerosis Deep Gray Matter Compared to Healthy Controls." Multiple Sclerosis and Related Disorders 33 (August 2019): 107–15. https://doi.org/10.1016/j.msard.2019.05.028. [60] Khalil, M., C. Langkammer, A. Pichler, D. Pinter, T. Gattringer, G. Bachmaier, S. Ropele, S. Fuchs, C. Enzinger, and F. Fazekas. "Dynamics of Brain Iron Levels in Multiple Sclerosis: A Longitudinal 3T MRI Study." Neurology 84, no. 24 (June 16, 2015): 2396-2402. https://doi.org/10.1212/WNL.000000000001679. [61] Gracien, René-Maxime, Sarah C. Reitz, Stephanie-Michelle Hof, Vinzenz Fleischer, Amgad Droby, Mathias Wahl, Helmuth Steinmetz, Sergiu Groppa, Ralf Deichmann, and Johannes C. Klein. "Longitudinal Quantitative MRI Assessment of Cortical Damage in Multiple Sclerosis: A Pilot Study: Longitudinal Cortical QMRI in MS." Journal of Magnetic Resonance 46, 5 (November 2017): 1485-90. *Imaging* no. https://doi.org/10.1002/jmri.25685. [62] Laule, Cornelia, I. M. Vavasour, K. P. Whittall, J. Oger, D. W. Paty, D. K. B. Li, A. L. MacKay, and D. L. Arnold. "Evolution of Focal and Diffuse magnetisation Transfer Abnormalities in Multiple Sclerosis." Journal of Neurology 250, no. 8 (August 2003): 924-31. https://doi.org/10.1007/s00415-003-1115-z. [63] Hayton, T., J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J. Tozer, D. H. Miller, and R. Kapoor. "Longitudinal Changes in Magnetisation Transfer

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

Ratio in Secondary Progressive Multiple Sclerosis: Data from a Randomised Placebo Controlled Trial of Lamotrigine." Journal of Neurology 259, no. 3 (March 2012): 505–14. https://doi.org/10.1007/s00415-011-6212-9. [64] Rocca, Maria A, Giovanna Mastronardo, Mariemma Rodegher, Giancarlo Comi, and Massimo Filippi. "Long-Term Changes of Magnetization Transfer-Derived Measures from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis," AJNR Am J Neuroradiol 20 (1999):821–827 [65] Weiskopf, Nikolaus, Siawoosh Mohammadi, Antoine Lutti, and Martina F. Callaghan. "Advances in MRI-Based Computational Neuroanatomy: Morphometry to in-Vivo Histology." Current Opinion in Neurology 28, no. 4 (August 2015): 313-22. https://doi.org/10.1097/WCO.000000000000222. [66] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation Study." NeuroImage 179 (October 2018): 117-33. https://doi.org/10.1016/j.neuroimage.2018.06.007. [67] Mangeat, G., S.T. Govindarajan, C. Mainero, and J. Cohen-Adad. "Multivariate Combination of Magnetization Transfer, T 2 * and B0 Orientation to Study the Myelo-Architecture of the in Vivo Human Cortex." NeuroImage 119 (October 2015): 89–102. https://doi.org/10.1016/j.neuroimage.2015.06.033.

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

[68] Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in Multiple Sclerosis." Neurology 68, no. Issue 22, Supplement 3 (May 29, 2007): S22-31. https://doi.org/10.1212/01.wnl.0000275229.13012.32. [69] Frischer, Josa M., Stephen D. Weigand, Yong Guo, Nilufer Kale, Joseph E. Parisi, Istvan Pirko, Jay Mandrekar, et al. "Clinical and Pathological Insights into the Dynamic Nature of the White Matter Multiple Sclerosis Plague: Dynamic Nature of MS Plague." **Annals** Neurology (November of 78. no. 5 2015): 710-21. https://doi.org/10.1002/ana.24497. [70] Lassmann, Hans, Wolfgang Brück, and Claudia Lucchinetti. "Heterogeneity of Multiple Sclerosis Pathogenesis: Implications for Diagnosis and Therapy." Trends in Molecular Medicine 7, no. 3 (March 2001): 115-21. https://doi.org/10.1016/S1471-4914(00)01909-2. [71] Lucchinetti, Claudia, Wolfgang Brück, Joseph Parisi, Bernd Scheithauer, Moses Rodriguez, and Hans Lassmann. "Heterogeneity of Multiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination." Annals of Neurology 47, no. 6 (June 2000): 707-17. https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q. [72] Dousset, Vincent, Annick Gayou, Bruno Brochet, and Jean-Marie Caille. "Early Structural Changes in Acute MS Lesions Assessed by Serial Magnetization Transfer

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

Studies." Neurology 51, 4 (October 1998): 1150-55. no. https://doi.org/10.1212/WNL.51.4.1150. [73] Levesgue, Ives R., Paul S. Giacomini, Sridar Narayanan, Luciana T. Ribeiro, John G. Sled, Doug L. Arnold, and G. Bruce Pike. "Quantitative Magnetization Transfer and Myelin Water Imaging of the Evolution of Acute Multiple Sclerosis Lesions: Quantitative MT and T₂ in Acute MS Lesions." Magnetic Resonance in Medicine 63, no. 3 (March 2010): 633-40. https://doi.org/10.1002/mrm.22244. [74] Elskamp, Ij van den, Dl Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L. Kappos, et al. "Lesional Magnetization Transfer Ratio: A Feasible Outcome for Remyelinating Treatment Trials in Multiple Sclerosis." Multiple Sclerosis Journal 16, no. 6 (June 2010): 660-69. https://doi.org/10.1177/1352458510364630. [75] Filippi, Massimo, Maria A. Rocca, Gianvito Martino, Mark A. Horsfield, and Giancarlo Comi. "Magnetization Transfer Changes in the Normal Appering White Matter Precede the Appearance of Enhancing Lesions in Patients with Multiple 1998): Sclerosis." Annals of Neurology 43, no. (June 809-14. https://doi.org/10.1002/ana.410430616. [76] Fazekas, F, S Ropele, C Enzinger, T Seifert, and S Strasser-Fuchs. "Quantitative Magnetization Transfer Imaging of Pre-Lesional White-Matter Changes in Multiple Multiple Sclerosis Journal 8, no. 6 (December 2002): 479-84. https://doi.org/10.1191/1352458502ms860oa.

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

[77] Zheng, Yufan, Jar-Chi Lee, Richard Rudick, and Elizabeth Fisher. "Long-Term Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions: Long-Term MTR Evolution in MS WM Lesions." Journal of Neuroimaging 28, no. 2 (March 2018): 191-98. https://doi.org/10.1111/jon.12480. [78] Chawla, Sanjeev, Ilya Kister, Tim Sinnecker, Jens Wuerfel, Jean-Christophe Brisset, Friedemann Paul, and Yulin Ge. "Longitudinal Study of Multiple Sclerosis Lesions Using Ultra-High Field (7T) Multiparametric MR Imaging." Edited by Quan Jiang. PLOS ONE 13, no. 9 (September 13, 2018): e0202918. https://doi.org/10.1371/journal.pone.0202918. [79] Lieury, Alice, Marie Chanal, Géraldine Androdias, Richard Reynolds, Sylvie Cavagna, Pascale Giraudon, Christian Confavreux, and Serge Nataf. "Tissue Remodeling in Periplaque Regions of Multiple Sclerosis Spinal Cord Lesions: Glia Remodeling in MS Cord." Spinal Glia 62, 10 (October 2014): 1645-58. no. https://doi.org/10.1002/glia.22705. [80] Kuhlmann, Tanja, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, and Hans Lassmann. "An Updated Histological Classification System for Multiple Sclerosis Lesions." Neuropathologica Acta 133, no. 1 (January 2017): 13-24. https://doi.org/10.1007/s00401-016-1653-y.

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

[81] Lassmann, Hans, Wolfgang Brück, and Claudia F. Lucchinetti. "The Immunopathology of Multiple Sclerosis: An Overview." Brain Pathology 17, no. 2 (April 2007): 210–18. https://doi.org/10.1111/j.1750-3639.2007.00064.x. [82] Dal-Bianco, Assunta, Günther Grabner, Claudia Kronnerwetter, Michael Weber, Romana Höftberger, Thomas Berger, Eduard Auff, et al. "Slow Expansion of Multiple Sclerosis Iron Rim Lesions: Pathology and 7 T Magnetic Resonance Imaging." Acta Neuropathologica 133, no. 1 (January 2017): 25-42. https://doi.org/10.1007/s00401-016-1636-z. [83] Elliott, Colm, Jerry S Wolinsky, Stephen L Hauser, Ludwig Kappos, Frederik Barkhof, Corrado Bernasconi, Wei Wei, Shibeshih Belachew, and Douglas L Arnold. "Slowly Expanding/Evolving Lesions as a Magnetic Resonance Imaging Marker of Chronic Active Multiple Sclerosis Lesions." Multiple Sclerosis Journal 25, no. 14 (December 2019): 1915-25. https://doi.org/10.1177/1352458518814117. [84] De Stefano, N., A. Giorgio, M. Battaglini, M. Rovaris, M. P. Sormani, F. Barkhof, T. Korteweg, et al. "Assessing Brain Atrophy Rates in a Large Population of Untreated Multiple Sclerosis Subtypes." Neurology 74, no. 23 (June 8, 2010): 1868-76. https://doi.org/10.1212/WNL.0b013e3181e24136. [85] Eshaghi, Arman, Ferran Prados, Wallace J. Brownlee, Daniel R. Altmann, Carmen Tur, M. Jorge Cardoso, Floriana De Angelis, et al. "Deep Gray Matter Volume Loss Drives

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

Disability Worsening in Multiple Sclerosis: Deep Gray Matter Volume Loss." Annals of Neurology 83, no. 2 (February 2018): 210-22. https://doi.org/10.1002/ana.25145. [86] Bermel, Robert A, and Rohit Bakshi. "The Measurement and Clinical Relevance of Brain Atrophy in Multiple Sclerosis." The Lancet Neurology 5, no. 2 (February 2006): 158-70. https://doi.org/10.1016/S1474-4422(06)70349-0. [87] Zivadinov, R., A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan. "Mechanisms of Action of Disease-Modifying Agents and Brain Volume Changes in Multiple Sclerosis." Neurology 71, no. 2 (July 8, 2008): 136-44. https://doi.org/10.1212/01.wnl.0000316810.01120.05. [88] De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi, Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia Sormani. "Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis." Journal of Neurology, Neurosurgery & Psychiatry, April 22, 2015, jnnp-2014-309903. https://doi.org/10.1136/jnnp-2014-309903. [89] on behalf of the MAGNIMS study group, Christian Enzinger, Frederik Barkhof, Olga Ciccarelli, Massimo Filippi, Ludwig Kappos, Maria A. Rocca, et al. "Nonconventional MRI and Microstructural Cerebral Changes in Multiple Sclerosis." Nature Reviews Neurology 11, no. 12 (December 2015): 676-86. https://doi.org/10.1038/nrneurol.2015.194.

[90] Bodini, Benedetta, Mattia Veronese, Daniel García-Lorenzo, Marco Battaglini, Emilie Poirion, Audrey Chardain, Léorah Freeman, et al. "Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis." *Annals of Neurology* 79, no. 5 (May 2016): 726–38. https://doi.org/10.1002/ana.24620.
[91] Patrikios, P., C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P. S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann. "Remyelination Is Extensive in a Subset of Multiple Sclerosis Patients." *Brain* 129, no. 12 (June 9, 2006): 3165–72. https://doi.org/10.1093/brain/awl217.